Style | Citing Format |
---|---|
MLA | H Taheri HOSSEIN, et al.. "The Multi-Voxel Mrs of Glioma: Glycine Is a Suitable Biomarker for Tumor Grading." Advanced Biomedical Research, vol. 14, no. 1, 2025, pp. -. |
APA | H Taheri HOSSEIN, S Hemati SIMIN, R Moghareabed REZA, Mb Tavakoli Mohammad BAGHER, A Forouzmehr ALI, S Mozafari SAFURA, N Abdi NEGAR, Y Nilie YASAMAN, H Taheri HAMED (2025). The Multi-Voxel Mrs of Glioma: Glycine Is a Suitable Biomarker for Tumor Grading. Advanced Biomedical Research, 14(1), -. |
Chicago | H Taheri HOSSEIN, S Hemati SIMIN, R Moghareabed REZA, Mb Tavakoli Mohammad BAGHER, A Forouzmehr ALI, S Mozafari SAFURA, N Abdi NEGAR, Y Nilie YASAMAN, H Taheri HAMED. "The Multi-Voxel Mrs of Glioma: Glycine Is a Suitable Biomarker for Tumor Grading." Advanced Biomedical Research 14, no. 1 (2025): -. |
Harvard | H Taheri HOSSEIN et al. (2025) 'The Multi-Voxel Mrs of Glioma: Glycine Is a Suitable Biomarker for Tumor Grading', Advanced Biomedical Research, 14(1), pp. -. |
Vancouver | H Taheri HOSSEIN, S Hemati SIMIN, R Moghareabed REZA, Mb Tavakoli Mohammad BAGHER, A Forouzmehr ALI, S Mozafari SAFURA, et al.. The Multi-Voxel Mrs of Glioma: Glycine Is a Suitable Biomarker for Tumor Grading. Advanced Biomedical Research. 2025;14(1):-. |
BibTex | @article{ author = {H Taheri HOSSEIN and S Hemati SIMIN and R Moghareabed REZA and Mb Tavakoli Mohammad BAGHER and A Forouzmehr ALI and S Mozafari SAFURA and N Abdi NEGAR and Y Nilie YASAMAN and H Taheri HAMED}, title = {The Multi-Voxel Mrs of Glioma: Glycine Is a Suitable Biomarker for Tumor Grading}, journal = {Advanced Biomedical Research}, volume = {14}, number = {1}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - H Taheri HOSSEIN AU - S Hemati SIMIN AU - R Moghareabed REZA AU - Mb Tavakoli Mohammad BAGHER AU - A Forouzmehr ALI AU - S Mozafari SAFURA AU - N Abdi NEGAR AU - Y Nilie YASAMAN AU - H Taheri HAMED TI - The Multi-Voxel Mrs of Glioma: Glycine Is a Suitable Biomarker for Tumor Grading JO - Advanced Biomedical Research VL - 14 IS - 1 SP - EP - PY - 2025 ER - |